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A genome-wide association study identiﬁes risk loci for
childhood acute lymphoblastic leukemia at 10q26.13
and 12q23.1
J Vijayakrishnan1, R Kumar2, MYR Henrion1, AV Moorman3, PS Rachakonda2, I Hosen2, MI da Silva Filho2, A Holroyd1, SE Dobbins1,
R Koehler4, H Thomsen2, JA Irving3, JM Allan3, T Lightfoot5, E Roman5, SE Kinsey6, E Sheridan7, PD Thompson8, P Hoffmann9,10,
MM Nöthen9, S Heilmann-Heimbach9, KH Jöckel11, M Greaves12, CJ Harrison3, CR Bartram4, M Schrappe13, M Stanulla14,
K Hemminki2,15 and RS Houlston1
Genome-wide association studies (GWASs) have shown that common genetic variation contributes to the heritable risk of
childhood acute lymphoblastic leukemia (ALL). To identify new susceptibility loci for the largest subtype of ALL, B-cell precursor ALL
(BCP-ALL), we conducted a meta-analysis of two GWASs with imputation using 1000 Genomes and UK10K Project data as reference
(totaling 1658 cases and 7224 controls). After genotyping an additional 2525 cases and 3575 controls, we identify new susceptibility
loci for BCP-ALL mapping to 10q26.13 (rs35837782, LHPP, P= 1.38 × 10− 11) and 12q23.1 (rs4762284, ELK3, P= 8.41 × 10− 9). We also
provide conﬁrmatory evidence for the existence of independent risk loci at 9p21.3, but show that the association marked by
rs77728904 can be accounted for by linkage disequilibrium with the rare high-impact CDKN2A p.Ala148Thr variant rs3731249. Our
data provide further insights into genetic susceptibility to ALL and its biology.
Leukemia advance online publication, 11 November 2016; doi:10.1038/leu.2016.271
INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the major pediatric cancer
in western countries, with B-cell precursor (BCP) ALL accounting
for ~ 80% of ALL cases.1 Despite this, the etiology of ALL is poorly
understood and although there is indirect evidence for an
infective origin, no speciﬁc environmental risk factor has been
identiﬁed.2,3 Evidence for inherited predisposition to ALL is
provided by the increased risk shown in siblings of cases
independent of the concordance in monozygotic twins, which
has an in utero etiology.4 Support for polygenic susceptibility to
ALL has come from genome-wide association studies (GWASs).5–9
Although these studies have so far identiﬁed single-nucleotide
polymorphisms (SNPs) at seven loci inﬂuencing BCP-ALL at 7p12.2
(IKZF1), 9p21.3 (CDKN2A, two risk loci), 10p12.2 (near PIP4K2A),
10p14 (GATA3), 10q21.2 (near ARID5B) and 14q11.2 (near CEBPE),
statistical modeling using genome-wide complex trait analysis
predicts that additional risk loci conferring modest effects should
be identiﬁable by further GWAS.10
Recovery of untyped genotypes through imputation provides a
mechanism of exploiting GWAS data sets to identify new risk
alleles.11 In addition, it enables ﬁne mapping and reﬁnement of
association signals, for example, in identiﬁcation of the CDKN2A
p.Ala148Thr variant rs3731249 (hg19 chr9:g.21970916 G4A) as
contributing to the 9p21.3 association signal.8 Recently, the use of
the 1000 Genomes Project and the UK10K projects as a combined
reference panel has been shown to improve imputation accuracy
compared with using the 1000 Genomes Project data alone.12,13
Here, we report imputation using the 1000 Genomes and the
UK10K Project data as reference and meta-analysis of two GWASs
to identify new susceptibility alleles for BCP-ALL. After replication
genotyping in three additional case–control series, we have
identiﬁed new risk loci for BCP-ALL at 10q26.13 and 12q23.1. Our
ﬁndings provide further insights into the genetic and biological
basis of this hematological malignancy.
MATERIALS AND METHODS
Ethics
Collection of samples and clinicopathological information from subjects
was undertaken with informed consent in accordance with the Declaration
of Helsinki and ethical board approval. Ethical committee approval was
obtained for Medical Research Council UKALL97/99 trial by individual UK
treatment centers and approval for UKALL2003 was obtained from the
Scottish Multi-Centre Research Ethics Committee (REC:02/10/052).14,15
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GWAS data
The UK-GWAS and German-GWAS data sets have been previously
reported.6,7 Brieﬂy, the UK-GWAS was based on constitutional DNA (that
is, remission samples) of 459 white BCP-ALL cases from the UK Childhood
Cancer Study (UKCCS; http://www.ukccs.org/; 258 males; mean age at
diagnosis 5.3 years); 342 cases from the UK Medical Research Council ALL
97/99 (1997–2002) trial (190 males; mean age of diagnosis 5.7 years) and
23 cases from the Northern Institute for Cancer Research (16 males).
Genotyping was performed using Illumina Human 317 K arrays (Illumina,
San Diego, CA, USA; Available at: http://www.illumina.com). For controls, we
used publicly accessible data generated by the Wellcome Trust Case Control
Consortium 2 (http://www.wtccc.org.uk/) from 2699 individuals in the 1958
British Birth Cohort (Hap1.2M-Duo Custom array data) and 2501 individuals
from the UK Blood Service. The German-GWAS was comprised of 1155 cases
(620 males; mean age at diagnosis 6.0 years) ascertained through the Berlin–
Frankfurt–Münster (BFM) trials (1993–2004) genotyped using the Illumina
Human OmniExpress-12v1.0 arrays. For controls, we used genotype data
from 2132 healthy individuals from the Heinz Nixdorf Recall study; consisting
of 704 individuals genotyped using Illumina HumanOmni1-Quad_v1 and
1428 individuals genotyped on Illumina Human OmniExpress-12v1.0 plat-
form. In total, we obtained 1658 BCP-ALL cases and 7224 matched controls
from the two GWASs series combined.
Quality control of GWAS samples
The quality-control steps of UK- and German-GWAS study samples have
been described in the previous studies.6,7 After the quality-control steps,
we obtained 824 cases and 5200 controls for the UK-GWAS data set, and
834 cases and 2024 controls from the German data sets that were then
used for further genotyping and imputation analysis.
Replication series and genotyping
The UK replication series comprised 1150 patients (504 males; mean age at
diagnosis 6.2 years) ascertained through the UK ALL-2003 (2003–2011) and
ALL 97/99 trials.14,15 Immunophenotyping of diagnostic samples was
undertaken using standard methods. The 2100 controls (702 males) were
ethnically-matched healthy individuals with no personal history of cancer
recruited to the National Study of Colorectal Cancer Genetics16 and the
Genetic Lung Cancer Predisposition Study.17 Genotyping of cases and
controls was performed using competitive allele-speciﬁc PCR KASPAR
chemistry (LCG Biosciences Ltd, Hertfordshire, UK). The German replication
series consisted of 1501 patients ascertained (794 males; mean age at
diagnosis, 6.2 years ascertained through the BFM trials (1993–2004)).18 The
controls comprised of 1516 (762 males; mean age, 58.2 years), ethnically
matched healthy individuals of German origin recruited at the Institute of
Transfusion Medicine in Manheim, Germany, 2004. Samples having SNP
call rates of o90% were excluded from the analysis. To ensure quality of
genotyping in all assays, at least 2 negative controls and 1 to 2% duplicates
(concordance 499.9%) were genotyped. All primers and probes used are
detailed in Supplementary Table S11. Combining both replication series,
we had access to 2651 B-cell ALL cases and 3616 matched controls for the
current study.
Sanger sequencing
To conﬁrm the ﬁdelity of imputation, a random subset of samples were
sequenced using BigDye Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems, Waltham, MA, USA) in conjunction with ABI 3700xl semi-
automated sequencers (Applied Biosystems). Primer sequences are
detailed in Supplementary Table S11.
Statistical and bioinformatics analyses
Main data analysis were undertaken using R version 2.15.2 (R Core Team,
2013; http://www.R-project.org/), PLINK v1.9(ref. 19) and SNPTEST v2.4.1
software.20 The two GWAS data sets were imputed for over 10 million
variants using IMPUTE2 v2.3.0 software21,22 and data from the
1000 Genomes Project (phase 1 integrated variant set, v3.20101123,
http://www.1000genomes.org, 9 December 2013) and UK10K (ALSPAC,
EGAS00001000090/EGAD00001000195; and TwinsUK, EGAS00001000108/
EGAD00001000194, studies only; http://www.uk10k.org/) as reference.
Data sets were ﬁrst phased using SHAPEIT v2.12 prior to imputation to
accurately estimate haplotypes.23 The adequacy of case–control matching
and possibility of differential genotyping between cases and controls were
evaluated using quantile–quantile plots of test statistics to compute λ100.
Test of association between imputed SNPs and childhood ALL was
performed using a missing data likelihood score test under a frequentist
additive model in software SNPTEST. Eigenvectors for the German data set
were inferred using smartpca component within EIGENSOFT v2.4(refs. 24,25)
and Eigenstrat adjustment was carried out by including the ﬁrst two
eigenvectors as covariates in SNPTEST during association analysis. Post
imputation and SNPTEST, only markers with info scores40.4, imputed call
rates/SNP 40.9, minor allele frequencies (MAFs) 40.005, and a posterior
imputation quality threshold of 0.5 or higher were included in further
analysis. SNPs that deviated from Hardy–Weinberg equilibrium at P-values
o10− 5 were also excluded from further analysis. Meta-analysis of post
quality control GWAS data sets was conducted in META 1.3.1,20,21,26 under
a ﬁxed-effects model using the inverse variance approach. We calculated
Cochran’s Q statistic to test for heterogeneity and the I2 statistic to quantify
the proportion of the total variation attributable to heterogeneity.27 The
presence of secondary association signals owing to allelic heterogeneity in
risk loci were carried out using a conditional analysis in SNPTEST by
adjusting for the sentinel SNP using the ‘–condition-on’ option. Logistic
regression association analysis and meta-analysis of the replication data
sets under ﬁxed effects were carried out using the STATA v.10 software
(Stata Corporation, College Station, TX, USA).
Linkage disequilibrium (LD) metrics were calculated using vcftools
v0.1.12b26 (http://vcftools.sourceforge.net) using UK10K data. HapMap
recombination rate (cM/Mb) were deﬁned by Oxford recombination
hotspots.28,29
Chromatin state dynamics and functional annotation
To explore the epigenetic proﬁle of association signals, we used 15-state
chromatin segmentation data learned by computationally integrating chIP-
seq data for GM12878 lymphoblastoid cells inferred from ENCODE Histone
Modiﬁcation data (H4K20me1, H3K9ac, H3K4me3, H3K4me2, H3K4me1,
H3K36me3, H3K27me3, H3K27ac and CTCF) and binarized using a
multivariate Hidden Markov Model (http://genome.ucsc.edu/ENCODE/).30
Risk SNPs and their proxies (that is, r240.8 in the 1000 Genomes EUR
reference panel) were annotated for putative functional effect using
HaploReg v3,31 RegulomeDB32 and SeattleSeq33 Annotation. These servers
make use of data from ENCODE,30 genomic evolutionary rate proﬁling34
conservation metrics, combined annotation-dependent depletion scores35
and PolyPhen scores.36 Similarly, we searched for overlap with ‘super-
enhancer’ regions as deﬁned by Hnisz et al.37 restricting analysis to
GM12878 cells.
Expression quantitative trait locus analysis
Expression quantitative trait locus (eQTL) analysis was performed for all
genes in 1 Mb regions spanning rs4762284 and rs35837782 by querying
messenger RNA expression data from MuTHER38 and Blood eQTL
browser.39
Chromosome karyotyping and 9p21.3 deletion status
Conventional cytogenetic studies on diagnostic ALL tumor cells were
conducted using standard karyotyping methodologies, and standard
criteria for the deﬁnition of a clone were applied. Genomic copy number
at 9p21.3 was assayed using FISH and MLPA as previously described.40,41
Relationship between SNP genotype and survivorship
To investigate if genotype is associated with clinical phenotype or
outcome, we analyzed data on patients recruited to AIEOP-BFM 2000.18
Brieﬂy, patients received standard chemotherapy (that is, prednisone,
vincristine, daunorubicin, l-asparaginase, cyclophosphamide, ifosfamide,
cytarabine, 6-mercaptopurine, 6-thioguanine and methotrexate) with a
subset of high-risk patients treated with cranial irradiation and/or stem cell
transplantation. Event-free survival was deﬁned as the time from diagnosis
to the date of last follow-up in complete remission or to the ﬁrst event.
Events were resistance to therapy (nonresponse), relapse, secondary
neoplasm or death from any cause. Failure to achieve remission owing to
early death or nonresponse was considered as an event at time zero and
patients lost to follow-up were censored at the time of their withdrawal.
Patients were stratiﬁed into three categories: standard, intermediate and
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high risk. Although minimal residual disease analysis was the main
stratiﬁcation criterion, high risk was also deﬁned by prednisone poor
response or ⩾ 5% leukemic blasts in bone marrow on day 33, or t(9;22)/
t(4;11) positivity or their molecular equivalents (BCR-ABL/MLL-AF4-fusion)
independent of minimal residual disease status. Standard patients were
minimal residual disease-negative on treatment day 33 (TP1) and 78 (TP2),
and had no high-risk criteria. High-risk patients were deﬁned as having
residual disease (⩾10−3 cells) at TP2. Intermediate patients had positive-
minimal residual disease detection at either TP1 or TP2, but had a cell
count of o10−3 at TP2. The Kaplan–Meier method was used to estimate
survival rates, differences were compared with the two-sided log-rank
test.42,43 Cumulative incidence functions for competing events were
constructed by the method of Kalbﬂeisch and Prentice,44 and were
compared employing the Gray’s test.45 Computations were performed
using SASv9.1 (SAS, Cary, NC, USA).
Heritability analysis
We used genome-wide complex trait analysis to estimate the polygenic
variance (that is, heritability) ascribable to all GWAS SNPs.46 SNPs were
excluded based on the MAF (o0.01), missing genotype rate (0.05) and
deviation from Hardy–Weinberg equilibrium (Po0.05). Individuals were
excluded for exhibiting an excess of missing genotype (40.02) and where
two individuals were closely related (genetic relatedness score 40.05).
A genetic relationship matrix of pairs of samples was used as input for the
restricted maximum likelihood analysis to estimate the heritability explained
by the selected set of SNPs. Regions of high LD in the genome were excluded
from the analysis. Imposing a prevalence of 0.0005(ref. 2) for childhood ALL,
we estimated the heritability explained by risk SNPs identiﬁed by GWAS as
located within autosomal regions associated with ALL. For each risk SNP, the
heritability was estimated for all chromosomes simultaneously using the risk
SNP genotype as a covariate. In chromosomes bearing multiple independent
risk loci, all the risk SNPs in that chromosome were used as covariates to get
the combined contribution of risk SNPs toward heritability. The heritability
associated with the risk SNPs was taken to be the difference between the
heritability of the chromosome on which it is found as calculated with and
without covariate adjustment for the SNP.
Calculation of polygenic risk scores
In addition to the two new risk loci described here, seven previously
reported risk loci were included in the calculation of the polygenic risk
scores for childhood ALL (rs10828317, 10p12.2; rs3824662, 10p14;
rs7089424, 10q21.2; rs2239633, 14q11.2; rs4132601, 7p12.2; rs3731249,
9p21.3; rs3731217, 9p21.3; rs35837782, 10q26.13; rs4762284, 12q23.1). The
eight variants are thought to act independently as previous studies have
shown no interaction between risk loci.5–7 Polygenic risk scores were
constructed using methods established by Pharoah et al.47 based on the
log-normal distribution LN(μ,σ2) of mean μ and variance σ2 (that is, relative
risk is normally distributed on a logarithmic scale). Standardized incidence
ratios for familial risk in singleton siblings and twins for childhood ALL
were assumed to be 3.2.4 Familial risk was calculated by dividing polygenic
variation over the square root of familial risk.
RESULTS
Association analysis
To identify new susceptibility loci for BCP-ALL, we conducted a
pooled meta-analysis of two GWASs in populations of European
ancestry, the UK-GWAS and the German-GWAS (see Materials and
Methods section). After ﬁltering, the studies provided genotype
data on 1658 cases and 7224 controls. To achieve consistent and
dense genome-wide coverage, we imputed unobserved geno-
types at 410 million SNPs using a combined reference panel
comprising 1092 individuals from the 1000 Genomes Project and
3781 individuals from the UK10K project (Supplementary
Figure S2). Quantile–quantile plots of SNPs (MAF 40.5%) post
imputation did not show evidence of substantive overdispersion
introduced by imputation (genomic inﬂation λ100 for UK- and
German-GWAS was 1.016 and 1.009, respectively; Supplementary
Figure S1).
Pooling data from both GWASs, we derived joint odds ratios
and 95% conﬁdence intervals under a ﬁxed-effects model for each
SNP with MAF40.5% and associated per allele P-values. From this
analysis, we identiﬁed the top-ranked SNPs in 20 distinct regions
and not previously implicated in the risk of developing BCP-ALL
(Supplementary Table S1). After conﬁrming the ﬁdelity of
imputation by Sanger sequencing (Supplementary Table S2), we
successfully designed and optimized allele-speciﬁc PCR (KASPAR)
assays for 14 SNPs. We sought validation of associations by
genotyping additional UK and German case–control series totaling
2525 cases and 3575 controls (Supplementary Table S3).
In the combined analysis of data from these replication series,
rs35837782 (10q26.13, hg19 chr10:g.126293309) and rs4762284
Table 1. Risk to childhood acute lymphoblastic leukemia at loci 10q26.13 and 12q23.1
rs35837782 (10q26.13, LHPP) Case genotypes Control genotypes OR 95% CI P-value
RAF AA AG GG RAF AA AG GG
UK-GWAS 0.67 93 358 373 0.62 745 2510 1945 1.27 (1.14–1.41) 2.04 × 10− 5
German-GWAS 0.67 93 365 376 0.63 268 952 804 1.19 (1.05–1.36) 0.0072
Meta 1.24 (1.14–1.34) 6.04 × 10− 7
UK replication 1 0.67 73 211 251 0.62 150 475 405 1.19 (1.03–1.39) 0.022
UK replication 2 0.67 56 265 253 0.61 167 497 391 1.33 (1.14–1.55) 0.0002
German replication 0.65 184 607 621 0.63 204 701 574 1.13 (1.02–1.26) 0.0203
Meta 1.20 (1.11–1.29) 3.66 × 10− 6
Combined meta 1.21 (1.15–1.28) 1.38× 10− 11 (Phet= 0.48, I
2= 0%)
rs4762284 (12q23.1, ELK3) RAF AA AT TT RAF AA AT TT OR 95% CI P-value
UK-GWAS 0.33 373 358 94 0.30 2578 2160 462 1.18 (1.05–1.32) 0.0046
German-GWAS 0.33 372 366 95 0.28 1072 773 179 1.30 (1.14–1.49) 1.01 × 10− 4
Meta 1.23 (1.13–1.34) 2.87 × 10− 6
UK replication 1 0.31 258 227 52 0.30 497 408 98 1.03 (0.88–1.21) 0.6870
UK replication 2 0.34 232 287 52 0.29 534 434 85 1.30 (1.11–1.53) 0.0008
German replication 0.31 650 625 124 0.28 746 619 109 1.15 (1.02–1.29) 0.0178
Meta 1.16 (1.07–1.25) 3.85× 10− 4
Combined meta 1.19 (1.12–1.26) 8.41 × 10−9 (Phet= 0.17, I
2= 38%)
Abbreviations: CI, conﬁdence interval; GWAS, genome-wide association study; OR, odds ratio; RAF, risk allele frequency. Risk allele for rs35837782 is G and risk
allele for rs4762284 is T.
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(12q23.1, hg19 chr12:g.96612762) showed signiﬁcant support for
an association with BCP-ALL, with P-values and odds ratios of
3.66 × 10− 6, 1.20 and 3.88 × 10− 4, 1.16, respectively (Table 1;
Supplementary Table S4; Supplementary Figure S3). In a meta-
analysis of the discovery GWAS and replication series, these
associations attained genome-wide signiﬁcance (rs35837782,
P= 1.38 × 10− 11 and rs4762284, P= 8.41 × 10− 9; Table 1;
Supplementary Table S4; Supplementary Figure S3).
Conditional association analyses
To explore the possibility of multiple risk loci at 10q26.13 and
12q23.1 and previously identiﬁed GWAS risk loci, we performed
conditional analyses. At 10q26.13 and 12q23.1, we found no
evidence for signals independent of SNPs rs35837782 and
rs4762284. Similarly at 7p12.2, 10p12.2, 10p14, 10q21.2 and
14q11.2, we found no support for the existence of multiple
risk loci.
We and others have recently sought to decipher the GWAS
signal at the 9p21.3 locus.8,48–50 Our conditional analysis supports
the assertion of an additional locus in this region, independent of
the original GWAS SNP rs3731217, which is best captured by the
rare coding SNP rs3731249 (MAF= 0.03, r2 = 0.005, D′= 1.00 with
rs3731217; Supplementary Table S5). rs3731249, encoding
CDKN2A p.Ala148Thr, has been shown to reduce tumor suppressor
function of p16INK4A, increase susceptibility to leukemic trans-
formation of hematopoietic progenitor cells and to be preferen-
tially retained in ALL cells.49 The more common variant rs662463
correlated with rs77728904 has concurrently been suggested as a
plausible causative variant underlying this new association
signal48 (MAF= 0.07, r2 = 0.16, D′= 1.00 with rs3731249). Despite
some evidence that rs77728904 variant is a cis-eQTL for CDKN2B,48
this association signal is entirely captured by rs3731249 (P-values
before and after conditioning: 6.26 × 10− 7and 0.10, respectively;
Supplementary Table S5). Here, our analysis has been constrained
to the identiﬁcation of variants that can be imputed with high
ﬁdelity, hence it does not exclude the possibility of rarer variants
with higher impact, especially indels potentially impacting on ALL
risk. This exempliﬁes the difﬁcultly in elucidating the genetic basis
of such functionally rich genomic regions. Once correcting for
these two signals, no additional statistically signiﬁcant association
was detected in this region.
Relationship between the new ALL-risk SNPs and tumor proﬁle
Given the biological heterogeneity of BCP-ALL, we analyzed the
association between rs35837782 and rs4762284 genotypes, and
the major subtypes of BCP-ALL, hyperdiploidy (that is, 450
chromosomes), ETV6-RUNX1 and others (Supplementary Table S6;
Supplementary Figure S3). Analysis of these data provided no
consistent evidence that the risk of rs35837782 and rs4762284
was conﬁned to hyperdiploid, ETV6-RUNX1 or non-hyperdiploid/
non-ETV6-RUNX1 subtypes of B-ALL. Similarly, we found no
evidence for a relationship between rs35837782 and rs4762284
genotypes, and other chromosomally deﬁned forms of BCP-ALL
deﬁned by t(9;22)(q34;q11), t(1;19)(q23;p13) and t(4;11)(q21;q23)
karyotype, or CDKN2A deletion status after adjustment for multiple
testing (Supplementary Table S6). Finally, we found no evidence
that rs35837782 and rs4762284 genotypes were associated with
age at diagnosis or sex, or inﬂuenced patient outcome as deﬁned
by event-free survival by analyzing data on 810 patients from the
AIEOP-BFM 2002 trial (Supplementary Figure S4, Supplementary
Table S7 and S8).
Impact on the heritable risk
By ﬁtting all SNPs from GWAS simultaneously, the estimated
heritability of ALL attributable to all common variation is 12.1%
(±3.8%). This estimate represents the additive variance, and
therefore, does not include the potential impact of gene–gene
interactions or dominance effects, or gene–environment interac-
tions impacting on ALL risk. Moreover, given the evidence, albeit
indirect, of a role for infectious exposure in relation to ALL risk, it is
possible that substantive gene–environment effects operate.
Although the currently identiﬁed risk SNPs (newly discovered
and previously identiﬁed) only account for 19% of the additive
heritable risk, the odds ratio effect sizes of the ALL-risk SNPs are
among the highest reported in GWAS of any cancer type, and in
combination they impact signiﬁcantly on disease risk with those in
the top 1% of genetic risk having a 6.2-fold relative risk of
developing ALL (Supplementary Figure S5). The power of our
GWAS to identify common alleles conferring relative risks of 1.5 or
greater (such as the 7p12.2 variant) is high (~80%). Hence, there
are unlikely to be many additional SNPs with similar effects for
alleles with frequencies40.3 in populations of European ancestry.
In contrast, our analysis had limited power to detect alleles with
smaller effects and/or MAF o0.1.
Biological inference
At 10q26.13, rs35837782 localizes to intron 6 on the gene
encoding phospholysine phosphohistidine inorganic pyropho-
sphate phosphatase (LHPP; Figure 1) with genes FAM53B and
METTL10 mapping nearby. The SNP rs4762284 at 12q23.1 maps to
intron 1 of the gene encoding the ETS-domain protein (ELK3), with
nearby genes including CDK17 (Figure 1).
To explore the epigenetic proﬁle of association signals at each
of the two new risk loci, we used HaploReg and RegulomeDB to
examine whether the sentinel SNPs and those in high LD (that is,
r240.8 in the 1000 Genomes EUR reference panel) annotate
putative transcription factor-binding or enhancer elements
(Supplementary Table S9). The SNP rs4762284 resides within a
region of open chromatin, common across multiple cell lines,
consistent with a regulatory element such as an enhancer or a
promoter. To gain further insight into the functional basis of
rs35837782 and rs4762284 associations, we examined for an
association between SNP genotype and expression of genes
mapping within 1 Mb of sentinel SNPs. We made use of publicly
available expression data on blood cells, lymphoblastoid cell lines
from HapMap3, Geneva and the Multiple Tissue Human Expres-
sion Resource pilot data. In blood, rs4762284 genotype was
associated with ELK3 expression at P= 6.85 × 10− 4 with the risk
allele correlated with reduced expression (Supplementary Table
S10).39
DISCUSSION
In this analysis of BCP-ALL, we have identiﬁed common variants at
10q26.13 and 12q23.1. It has recently been proposed that many
GWAS signals are a consequence of ‘synthetic associations’,
resulting from the combined effect of one or more rare causal
variants rather than simply LD with a common risk variant.51,52
Support for such a model in ALL is provided by the rare high-
impact variant rs3731249 in CDKN2A8 that is in LD with
rs77728904. As imputation using UK10K as reference can
accurately recover genotypes for variants with MAFs of 0.5%,12
the possibility that either 10q26.13 or 12q23.1 associations have a
similar genetic basis is highly unlikely.
Given the existence of immunogenetic subtypes of BCP-ALL, it
is perhaps not surprising there is variability in the genetic effects
on ALL risk by subtype, with 10q21.2 variants inﬂuencing
hyperdiploid ALL and 10p14 variants inﬂuencing non-hyperdi-
ploid/non-ETV6-RUNX1 disease.6,7 In contrast to the 7p12.2 and
10p12.2 risk variants,6,7 the 10q26.13 and 12q23.1 loci have
generic effects on the development of ALL.
Because rs35837782 and rs4762284 localize to LHPP and ELK3,
respectively, it is plausible that the functional basis of these
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Figure 1. Regional plots of association results and recombination rates for the newly identiﬁed risk loci for BCP-ALL (a and b). Results for
10q26.13 (rs35837782, a) and 12q23.1 (rs4762284, b). Plots (using visPig)56 show association results of both genotyped (triangles) and imputed
(circles) SNPs in the GWAS samples and recombination rates. − log10 P-values (y axes) of the SNPs are shown according to their chromosomal
positions (x axes). The sentinel SNP in each combined analysis is shown as a large circle or triangle, and is labeled by its rsID. The color
intensity of each symbol reﬂects the extent of LD with the top genotyped SNP, white (r2= 0) through to dark red (r2= 1.0). Genetic
recombination rates, estimated using UK10K Genomes Project samples, are shown with a light-blue line. Physical positions are based on NCBI
build 37 of the human genome. Also shown are the relative positions of genes and transcripts mapping to the region of association. Genes
have been redrawn to show their relative positions; therefore, maps are not to physical scale. The lower panel is the chromatin-state
segmentation track (ChromHMM) for lymphoblastoid cells using data from the HapMap ENCODE Project. CNV, copy-number variation.
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associations are mediated through these genes. ELK3, an ETS-
domain transcription factor is an attractive candidate for
deﬁning ALL susceptibility a priori as it has a role in both B-cell
development and IgH gene regulation.53 ELK3, which is a
member of ETS family of transcription factors, interacting with
TCF3 transcription factor 3 (E2A immunoglobulin enhancer-
binding factors E12/E47) that is involved in several ALL-speciﬁc
gene fusions including TCF3-PBX1/t(1;19)(q23;p13) and TCF3-
HLF/t(17;19)(q23;p13) ALL.54 ELK3 is highly expressed primarily
at the early stages of B-lymphocyte development with expres-
sion declining drastically upon B-cell maturation, correlating
with the activity of the enhancer of the immunoglobulin heavy
chain.53 Hence, genetically determined reduced expression is
compatible with B-cell developmental arrest, a hallmark of ALL.
In contrast to ELK3 evidence for a role for LHPP, which encodes a
diphosphatase, in B-cell development or B-cell malignancy is yet
to be established.55 Although the identiﬁed risk SNPs map
within regions of active chromatin within B cells and thus have a
role in the B-cell cis-regulatory network a priori, additional
laboratory follow-up is required to decipher their functional
basis.
In summary, our ﬁndings represent a further important step in
deﬁning the contribution of inherited genetic variants to the risk
of developing ALL. Our current and previous ﬁndings are notable
because we have deﬁned associations of several regions with
susceptibility to ALL, and these regions harbor plausible candidate
genes for further investigation. Moreover, they emphasize the role
of genetically determined expression of B-cell developmental
genes being key players in ALL. Given that there remains
signiﬁcant missing heritability for ALL, future GWAS-based studies
in concert with functional analyses are likely to lead to further
insights into ALL biology.
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